Sovereign in Oncology. Sovereign in Operation.

Naprod Life Sciences Pvt. Ltd. is a manufacturer of sterile and non-sterile pharmaceutical products, built around three therapeutic lines: oncology, anesthesia, and critical-care injectables. Manufacturing is consolidated at a single site — MIDC Tarapur, Boisar, Maharashtra, India (DUNS 915076185) — where lyophilized injectables, liquid injectables, tablets, and capsules are formulated, filled, and released under one quality system. Naprod also carries a dedicated Contract Development and Manufacturing Organization (CDMO) capability for partners who need process development and manufacturing scale on top of the existing plant infrastructure — a service built on the same regulatory base as the branded catalog, not a separate business.

Naprod began production of oncology, anesthesia, and critical-care injectables at Boisar, Maharashtra in 1994; the company was formally incorporated in 2006. Lyophilization capability was added at the Tarapur facility to extend beyond liquid formulations, and the plant subsequently earned WHO-GMP certification, opening pathways into regulatory frameworks that reference WHO-GMP-listed manufacturers. Latin American market entry followed direct ANVISA (Brazil) and INVIMA (Colombia) regulatory approvals, and EU-GMP certification later enabled direct supply into European Economic Area markets. Most recently, ANVISA renewed the Tarapur plant's GMP certification in January 2026, reaffirming continuous Brazilian market access — reported by Pharma India Magazine.

Pending approval Dates between the 1994 founding and the January 2026 ANVISA renewal are sourced from an internal IT-team draft and are pending confirmation against company records.

The Tarapur facility runs six declared production lines: oncology lyophilized injectables, oncology liquid injectables, tablets, capsules, general lyophilized injectables, and general liquid injectables. The current catalog spans 163 products — 100 finished dosage form (FDF) and 63 active pharmaceutical ingredient (API) — sold across SRA/EU export, rest-of-world (ROW) export, and domestic tiers. API supply is produced by MacChem, presented here as a group company.

Pending approval Annual capacity figures (oncology lyophilized 3.5M units, oncology liquid 3M, tablets 30M, capsules 15M, general lyophilized 10M, general liquid 1M) are carried over from a company draft and are pending confirmation.

Naprod's Tarapur facility holds direct plant-level accreditation from EU-GMP, ANVISA (Brazil), INVIMA (Colombia), the UAE Ministry of Health and Prevention, Bahrain's National Health Regulatory Authority, and WHO-GMP — each confirmed against an official regulator source. A further slate of national agency relationships across Latin America, Africa, Southeast Asia, CIS/Ukraine, and South Asia is on record internally and is being digitized toward a target register of roughly 21 accreditations.

Pending approval Beyond the six independently verified accreditations, the wider ~21-agency register is an internal draft awaiting company sign-off before publication as verified.

Mohan B. Jain serves as Director of Naprod Life Sciences Pvt. Ltd., overseeing the Tarapur manufacturing base. He is currently the only Naprod leader approved for public identification on this site.

Pending approval The wider leadership team (CEO, COO, Head of Quality Assurance, Head of Manufacturing Operations, Head of R&D) is PENDING APPROVAL and withheld from public identification until the company confirms names and titles.

Naprod orients daily manufacturing and quality decisions around seven standing values: quality without compromise, regulatory integrity, reliability of supply, scientific rigor, people first, continuous improvement, and responsible operations. Each value maps to a concrete operating discipline — documented GMP release criteria, transparent regulator and customer communication, capacity planning for supply continuity, validated-data-driven process decisions, trained and accountable shift teams, a standing review cadence rather than deviation-only reviews, and environmental/health/safety practice treated as a standing requirement at the Tarapur site.

Pending approval The seven values listed are placeholders pending confirmation — Naprod's live-site values are authoritative and were not recoverable from available source material; this set must be replaced with the company-confirmed list before publishing.